Revolution Medicines is a clinical-stage precision oncology company dedicated to developing innovative targeted therapies. Their primary focus is on combating elusive frontier targets within notorious growth and survival pathways, with a particular emphasis on RAS and associated signaling pathways. By leveraging their deep understanding of genetic drivers and adaptive resistance mechanisms in cancer, coupled with robust drug discovery and medicinal chemistry capabilities, Revolution Medicines is building a portfolio of compounds that inhibit critical signaling nodes within these pathways.

Their approach involves advanced structure-based drug discovery techniques to access unconventional sites on challenging targets, utilizing differentiated methods such as intra-molecular allosteric binding and tri-complex formation. This comprehensive strategy enables them to explore mechanism-based dosing paradigms and in-pathway combinations, optimizing cancer treatment for patients. Their most advanced product candidate, RMC-4630, is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway.

Additionally, Revolution Medicines is developing a portfolio of mutant-selective RAS inhibitors, including RAS(ON), the first potent and selective inhibitors of the active, GTP-bound form of RAS. Recognizing the phenomenon of oncogene addiction and adaptive resistance, Revolution Medicines is pursuing combination therapy and monotherapy development strategies for their programs. With an exceptional team and state-of-the-art facilities in the heart of the Bay Area, Revolution Medicines is at the forefront of translating frontier oncology targets to outsmart cancer™